Clinical Trial Update: A Study to Assess Drug Absorption of Fixed Dose Combinations of Budesonide, Glycopyrronium, and Formoterol [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating absorption of fixed-dose combinations of budesonide, glycopyrronium, and formoterol in COPD patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• budesonide/glycopyrronium/formoterol fixed-dose combination

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease (COPD) | Phase 1 | Status: COMPLETED | Results posted: 2023-01-23